Observational studyArtificial organs2026
Determinants of Intradialytic Phosphate Removal in Hemodiafiltration From Real-World Clinical Practice.
Observational study in Artificial organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHyperphosphatemia is frequent in hemodialysis (HD) patients and associates with cardiovascular mortality. Parameters of online hemodiafiltration (OL-HDF) prescription influencing phosphate removal are poorly understood in real-world clinical settings.
methodsWe conducted a prospective observational study including chronic HD patients dialyzed at a single UK university hospital between December 2021 and July 2023. Phosphate removal was quantified from spent dialysate during a midweek session.
resultsDialysate phosphate was measured during 161 dialysis sessions in 128 unique patients (19 on HD and 109 on OL-HDF), with mean age 63.3 ± 16.2 years and 77 (60.1%) men. Mean intra-dialytic phosphate removal was 25.6 ± 14.3 mmol per session. In multivariate analysis, pre-HD serum phosphate concentration, session time, and urea distribution volume (V) were positively associated with intradialytic phosphate removal. A significant interaction between session time and pre-HD serum phosphate concentration indicated that longer sessions provided greater benefit to patients with higher baseline phosphate levels. Conversely, dialysis modality (OL-HDF vs. HD) and substitution volume were not significantly associated with phosphate removal.
conclusionsOL-HDF and substitution flow do not demonstrate a measurable beneficial impact on phosphate removal in a real-world setting. Session time, pre-HD serum phosphate concentration, and urea distribution volume (V) are the most relevant determinants of phosphate clearance in real-world clinical practice. Session duration emerges as the most effective modifiable factor for controlling phosphate burden in dialysis patients, particularly for those with higher pre-HD phosphate levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.